Tag Archive for: Biogen

Intravenous treatment of the drug, co-developed with U.S. partner Biogen (BIIB.O), will cost about 2.98 million yen ($20,438) per patient per year.

According to Sage Therapeutics, U.S. wholesalers are expected to pay almost $16,000 for the full 14-day treatment.

Subcutaneous injections of Eisai and Biogen’s Leqembi lead to numerically greater amyloid removal than the intravenous version of the Alzheimer’s disease therapy, though risks of brain swelling and bleeding remain.

Roche and its subsidiaries Genentech and Chugai Pharmaceutical jointly told the court without providing further details that they, Biogen and its manufacturer Bio-Thera had agreed to settle the case.

The layoffs, set to take effect in late November, will impact about a third of Reata’s headcount. The workforce reduction comes just months after Biogen’s $7.3 billion Reata buy.

The development comes after a health ministry panel recommended the drug’s approval in August, followed by standard approval from the U.S. Food and Drug Administration (FDA) in July.

Interim data from the Phase III innovaTV 301 trial showed that Genmab and Seagen’s antibody-drug conjugate Tivdak (tisotumab vedotin-tftv) met its primary endpoint, leading to significant survival benefit in patients with metastatic cervical cancer, the companies announced Monday.

Sage Therapeutics said on Thursday it plans to lay off about 188 people, or about 40% of its workforce, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder.

The FDA on Thursday approved Sandoz’s Tyruko (natalizumab-sztn), a biosimilar of Biogen’s blockbuster treatment Tysabri (natalizumab), a monotherapy for the treatment of adults with relapsing forms of multiple sclerosis.

A Japanese health ministry panel on Monday recommended approval of the Alzheimer’s disease treatment Leqembi, following standard approval for the drug granted by U.S. regulators last month.